- Article
Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients—Focus on Clinical and Histopathological Variation
- Dennis Niebel,
- Dagmar Wilsmann-Theis,
- Thomas Bieber,
- Mark Berneburg,
- Joerg Wenzel and
- Christine Braegelmann
Background: The most common autoimmune blistering disease, bullous pemphigoid (BP), shows an increased prevalence in psoriatic patients and oncologic patients undergoing immune-checkpoint blockade (ICB). Even though the same autoantigens (BP180/BP230...

